Bacteria can be engineered to metabolize inflammation by-products for the treatment of inflammation-mediated diseases. We created a spin-off company to translate bioengineered Escherichia coli Nissle into a live therapeutic product, navigating translational, regulatory and biotech mindset challenges. Here, I provide some generalizable insights into academic entrepreneurship.